75 related articles for article (PubMed ID: 22828407)
21. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
Guerreiro AS; Fattet S; Fischer B; Shalaby T; Jackson SP; Schoenwaelder SM; Grotzer MA; Delattre O; Arcaro A
Clin Cancer Res; 2008 Nov; 14(21):6761-9. PubMed ID: 18980969
[TBL] [Abstract][Full Text] [Related]
22. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
[TBL] [Abstract][Full Text] [Related]
23. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors.
Carlo-Stella C; Tabilio A; Regazzi E; Garau D; La Tagliata R; Trasarti S; Andrizzi C; Vignetti M; Meloni G
Bone Marrow Transplant; 1997 Sep; 20(6):465-71. PubMed ID: 9313879
[TBL] [Abstract][Full Text] [Related]
24. The inhibitory effect of human macrophage inflammatory protein-1 alpha (LD78) on acute myeloid leukemia cells in vitro.
Basara N; Stosić-Grujicić S; Sefer D; Ivanović Z; Antunović P; Milenković P
Stem Cells; 1996 Jul; 14(4):445-51. PubMed ID: 8843546
[TBL] [Abstract][Full Text] [Related]
25. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.
Pillinger G; Loughran NV; Piddock RE; Shafat MS; Zaitseva L; Abdul-Aziz A; Lawes MJ; Bowles KM; Rushworth SA
Oncotarget; 2016 Jun; 7(26):39784-39795. PubMed ID: 27174919
[TBL] [Abstract][Full Text] [Related]
26. Role of suramin as an IL-1 inhibitor in suppression of acute myelogenous leukemia progenitor proliferation.
Estrov Z; Talpaz M; Estey EH; Strassmann G
Exp Hematol; 1995 Sep; 23(10):1080-7. PubMed ID: 7544738
[TBL] [Abstract][Full Text] [Related]
27. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
[TBL] [Abstract][Full Text] [Related]
28. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
29. [The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia].
Dos Santos C; Récher C; Demur C; Payrastre B
Bull Cancer; 2006 May; 93(5):445-7. PubMed ID: 16777621
[TBL] [Abstract][Full Text] [Related]
30. Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.
Bruce I; Akhlaq M; Bloomfield GC; Budd E; Cox B; Cuenoud B; Finan P; Gedeck P; Hatto J; Hayler JF; Head D; Keller T; Kirman L; Leblanc C; Le Grand D; McCarthy C; O'Connor D; Owen C; Oza MS; Pilgrim G; Press NE; Sviridenko L; Whitehead L
Bioorg Med Chem Lett; 2012 Sep; 22(17):5445-50. PubMed ID: 22863202
[TBL] [Abstract][Full Text] [Related]
31. A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
Wang X; Li JP; Yang Y; Ding J; Meng LH
Acta Pharmacol Sin; 2013 Sep; 34(9):1201-7. PubMed ID: 23892273
[TBL] [Abstract][Full Text] [Related]
32. Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia.
Evangelisti C; Evangelisti C; Bressanin D; Buontempo F; Chiarini F; Lonetti A; Soncin M; Spartà A; McCubrey JA; Martelli AM
Expert Opin Ther Targets; 2013 Aug; 17(8):921-36. PubMed ID: 23755894
[TBL] [Abstract][Full Text] [Related]
33. A critical role for Lyn in acute myeloid leukemia.
Dos Santos C; Demur C; Bardet V; Prade-Houdellier N; Payrastre B; Récher C
Blood; 2008 Feb; 111(4):2269-79. PubMed ID: 18056483
[TBL] [Abstract][Full Text] [Related]
34. p110α and p110β isoforms of PI3K signaling: are they two sides of the same coin?
Singh P; Dar MS; Dar MJ
FEBS Lett; 2016 Sep; 590(18):3071-82. PubMed ID: 27552098
[TBL] [Abstract][Full Text] [Related]
35. Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing Phosphoinositide 3-kinase (PI3K) p110β isoform inhibitors through structure-based fragment optimisation.
Giordanetto F; Wållberg A; Cassel J; Ghosal S; Kossenjans M; Yuan ZQ; Wang X; Liang L
Bioorg Med Chem Lett; 2012 Nov; 22(21):6665-70. PubMed ID: 23010274
[TBL] [Abstract][Full Text] [Related]
36. Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα.
Nacht M; Qiao L; Sheets MP; St Martin T; Labenski M; Mazdiyasni H; Karp R; Zhu Z; Chaturvedi P; Bhavsar D; Niu D; Westlin W; Petter RC; Medikonda AP; Singh J
J Med Chem; 2013 Feb; 56(3):712-21. PubMed ID: 23360348
[TBL] [Abstract][Full Text] [Related]
37. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia.
Järås M; Miller PG; Chu LP; Puram RV; Fink EC; Schneider RK; Al-Shahrour F; Peña P; Breyfogle LJ; Hartwell KA; McConkey ME; Cowley GS; Root DE; Kharas MG; Mullally A; Ebert BL
J Exp Med; 2014 Apr; 211(4):605-12. PubMed ID: 24616378
[TBL] [Abstract][Full Text] [Related]
38. Activation of GPR44 decreases severity of myeloid leukemia via specific targeting of leukemia initiating stem cells.
Qian F; Nettleford SK; Zhou J; Arner BE; Hall MA; Sharma A; Annageldiyev C; Rossi RM; Tukaramrao DB; Sarkar D; Hegde S; Gandhi UH; Finch ER; Goodfield L; Quickel MD; Claxton DF; Paulson RF; Prabhu KS
Cell Rep; 2023 Jul; 42(7):112794. PubMed ID: 37459233
[TBL] [Abstract][Full Text] [Related]
39. Phosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients.
Ruvolo PP; Qiu Y; Coombes KR; Zhang N; Neeley ES; Ruvolo VR; Hail N; Borthakur G; Konopleva M; Andreeff M; Kornblau SM
BBA Clin; 2015 Dec; 4():59-68. PubMed ID: 26674329
[TBL] [Abstract][Full Text] [Related]
40. PI3Kα inhibition reduces obesity in mice.
Lopez-Guadamillas E; Muñoz-Martin M; Martinez S; Pastor J; Fernandez-Marcos PJ; Serrano M
Aging (Albany NY); 2016 Nov; 8(11):2747-2753. PubMed ID: 27816049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
